This Weight Loss Stock Could Skyrocket by 462%, According to Wall Street
Last year, Viking Therapeutics, a mid-cap biotech, made waves after it reported excellent phase 2 results for an investigational medicine for weight loss, the industry's hottest and perhaps fastest-growing therapeutic area. Analysts remain bullish on Viking, but another weight loss company boasts even more significant upside potential, judging by Wall Street's predictions: Terns Pharmaceuticals (NASDAQ: TERN).The average price target for this small-cap drugmaker's stock, $19.06 (per Yahoo! Finance), implies that the stock could skyrocket by about 462% from its current levels. Does that make it a buy?Terns Pharmaceuticals focuses on developing weight loss and oncology medicines. Its two leading candidates, TERN-601 and TERN-501 -- both in the anti-obesity field -- are close to entering phase 2 studies. The stock's returns in the next few years will depend on clinical and regulatory progress for these and other investigational medicines. Are they promising enough to warrant Wall Street's bullish predictions?Continue reading
Last year, Viking Therapeutics, a mid-cap biotech, made waves after it reported excellent phase 2 results for an investigational medicine for weight loss, the industry's hottest and perhaps fastest-growing therapeutic area. Analysts remain bullish on Viking, but another weight loss company boasts even more significant upside potential, judging by Wall Street's predictions: Terns Pharmaceuticals (NASDAQ: TERN).
The average price target for this small-cap drugmaker's stock, $19.06 (per Yahoo! Finance), implies that the stock could skyrocket by about 462% from its current levels. Does that make it a buy?
Terns Pharmaceuticals focuses on developing weight loss and oncology medicines. Its two leading candidates, TERN-601 and TERN-501 -- both in the anti-obesity field -- are close to entering phase 2 studies. The stock's returns in the next few years will depend on clinical and regulatory progress for these and other investigational medicines. Are they promising enough to warrant Wall Street's bullish predictions?
